THE ROLE OF HORMONAL THERAPY FOR PREMENOPAUSAL WOMEN, WITH EARLY STAGES HORMONE RECEPTOR POSITIVE BREAST CANCER

  • Dr. Ali K. Shaaeli Consultant Surgeon, Dept. of surgery, College of Medicine, University of Babylon, Iraq
  • Dr. Alaa Sadeq Alawad Consultant Physician, College of Medicine, Dept. of Oncology, University of Babylon, Iraq
  • Dr. Heider Kereem Ameen Specialist surgeon, Al Hilla Teaching Hospital, Dept. of Surgery. Babylon, Iraq
Keywords: Brest cancer, Tamoxifen, Goserelin

Abstract

Aim: To highlight Tamoxifen and ovarian suppression as effective adjuvant approaches for premenopausal steroid receptor-positive breast cancer. In addition to encouraging surgeons toward breast-conserving surgery with these effective adjuvant approaches.

Patients and Methods: Premenopausal women with early stages, steroid hormone receptor-positive breast cancer, 100 selected patients, for the retrospective study were randomly assigned to six or eight cycles of chemotherapy. Followed by two years of monthly Goserelin, and daily Tamoxifen for five years. The primary endpoints were time to recurrence (TTR) for Tamoxifen alone therapy versus combined Tamoxifen and Goserelin therapy.

Results: With a two-year follow-up, the combination of Tamoxifen and Goserelin show improved time to recurrence (TTR).

Conclusion: Combination of Tamoxifen and Goserelin improves outcomes for premenopausal stage1, II and IIIA, hormone receptor-positive breast cancer.

Downloads

Download data is not yet available.

References

1. Bardou V-J, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. Journal of Clinical Oncology. 2003;21(10):1973-9.
2. Jones N.L JH, L. CURRENT OBSTETRIC AND GYNECOLOGIC DIAGNOSIS&TREATMENT. 9 ed2003 2003. 1018-40 p.
3. Hunt K.K NLA, Copeland E.m, Bland K.I Schwart's principles of surgery. 9 ed. NewYork: McGraw-Hill; 2010. 423-74 p.
4. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study. International journal of cancer. 2000;89(2):111-7.
5. Fernö M, Stål O, Baldetrop B, Hatschek T, Källström A-C, Malmström P, et al. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. Breast cancer research and treatment. 2000;59(1):69-76.
6. Committe JF. British National Formulary 56. September. BMJ and RPS Publishing, London. 2008.
7. Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). Journal of clinical oncology. 2005;23(25):5973-82.
8. Daniel WW. Biostatistics: a foundation for analysis in the health sciences. New York, USA. 1995.
How to Cite
1.
Shaaeli AK, Alawad AS, Ameen HK. THE ROLE OF HORMONAL THERAPY FOR PREMENOPAUSAL WOMEN, WITH EARLY STAGES HORMONE RECEPTOR POSITIVE BREAST CANCER. Med. res. chronicles [Internet]. 2015Jul.15 [cited 2024Nov.25];2(4):476-82. Available from: https://medrech.com/index.php/medrech/article/view/110
Issue
Vol. 2 No. 4 (2015): Jul-Aug
Section
Original Research Article